Keeps Biopharma Inc. (KOSDAQ:256940)
South Korea · Delayed Price · Currency is KRW 8,460.00
-130.00 (-1.51%)
At close: Apr 17, 2026
Keeps Biopharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 170,147 | 127,583 | 92,133 | 14,617 | 4,261 |
Other Revenue | - | -0 | - | - | 0 |
| 170,147 | 127,583 | 92,133 | 14,617 | 4,261 | |
Revenue Growth (YoY) | 33.36% | 38.48% | 530.30% | 243.09% | -72.00% |
Cost of Revenue | 132,570 | 110,343 | 79,336 | 13,574 | 5,050 |
Gross Profit | 37,576 | 17,240 | 12,798 | 1,044 | -788.97 |
Selling, General & Admin | 30,741 | 9,921 | 7,302 | 6,076 | 5,475 |
Research & Development | 2,591 | 801.38 | 1,450 | 2,164 | 2,810 |
Amortization of Goodwill & Intangibles | 2,189 | 708.06 | 27.97 | 42.45 | 39.42 |
Other Operating Expenses | 369.65 | 226.14 | 441.16 | 41.37 | 46.25 |
Operating Expenses | 36,002 | 11,015 | 9,738 | 9,958 | 11,518 |
Operating Income | 1,575 | 6,225 | 3,060 | -8,915 | -12,307 |
Interest Expense | -7,165 | -3,731 | -2,030 | -934.7 | -1,690 |
Interest & Investment Income | 1,201 | 733.24 | 1,012 | 1,075 | 431.37 |
Earnings From Equity Investments | -1,763 | -1,609 | 4,930 | -3,998 | -3,081 |
Currency Exchange Gain (Loss) | -674.3 | 2,307 | 531.9 | 1,480 | 1,869 |
Other Non Operating Income (Expenses) | -2,238 | -1,127 | -3,132 | -3,237 | 10.54 |
EBT Excluding Unusual Items | -9,065 | 2,798 | 4,372 | -14,530 | -14,767 |
Impairment of Goodwill | - | -81.54 | - | - | - |
Gain (Loss) on Sale of Investments | -2,633 | 847.49 | 1,033 | -203.11 | -2,519 |
Gain (Loss) on Sale of Assets | -6.22 | 24.15 | -33.36 | 2.44 | -19.15 |
Asset Writedown | - | -302.3 | - | - | - |
Other Unusual Items | - | 83.7 | - | 853.14 | - |
Pretax Income | -11,703 | 3,370 | 5,372 | -13,877 | -17,305 |
Income Tax Expense | -1,321 | 1,758 | 1,909 | -1,837 | -1,074 |
Earnings From Continuing Operations | -10,383 | 1,612 | 3,463 | -12,040 | -16,231 |
Minority Interest in Earnings | 597.42 | -498.28 | 467.19 | 665.13 | 913.17 |
Net Income | -9,785 | 1,113 | 3,930 | -11,375 | -15,317 |
Net Income to Common | -9,785 | 1,113 | 3,930 | -11,375 | -15,317 |
Net Income Growth | - | -71.67% | - | - | - |
Shares Outstanding (Basic) | 20 | 19 | 19 | 19 | 17 |
Shares Outstanding (Diluted) | 20 | 19 | 19 | 19 | 17 |
Shares Change (YoY) | 3.91% | 0.31% | 0.40% | 8.22% | 18.22% |
EPS (Basic) | -499.00 | 59.00 | 209.62 | -607.03 | -884.60 |
EPS (Diluted) | -499.00 | 59.00 | 209.00 | -607.03 | -884.60 |
EPS Growth | - | -71.77% | - | - | - |
Free Cash Flow | -46,854 | -1,787 | -1,048 | -962.12 | -8,471 |
Free Cash Flow Per Share | -2389.34 | -94.70 | -55.71 | -51.34 | -489.19 |
Gross Margin | 22.09% | 13.51% | 13.89% | 7.14% | -18.52% |
Operating Margin | 0.92% | 4.88% | 3.32% | -60.99% | -288.86% |
Profit Margin | -5.75% | 0.87% | 4.27% | -77.82% | -359.52% |
Free Cash Flow Margin | -27.54% | -1.40% | -1.14% | -6.58% | -198.82% |
EBITDA | 6,063 | 8,807 | 4,502 | -7,921 | -11,495 |
EBITDA Margin | 3.56% | 6.90% | 4.89% | -54.19% | -269.79% |
D&A For EBITDA | 4,488 | 2,582 | 1,442 | 993.33 | 812.4 |
EBIT | 1,575 | 6,225 | 3,060 | -8,915 | -12,307 |
EBIT Margin | 0.92% | 4.88% | 3.32% | -60.99% | -288.86% |
Effective Tax Rate | - | 52.17% | 35.53% | - | - |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.